Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | LTB4R | Q15722 | 3/20 | 0.47 |
| ▸ | LTB4R2 | Q9NPC1 | 3/20 | 0.47 |
| ▸ | FPR3 | P25089 | 1/20 | 0.45 |
| ▸ | FPR2 | P25090 | 1/20 | 0.45 |
| ▸ | ESRRG | P62508 | 1/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 2/20 | 0.39 |
| ▸ | PPARA | Q07869 | 2/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 2/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2191105 | 0.91 | TAAR1 (0.44) | TAAR1LTB4RLTB4R2FPR3FPR2 | |
| SCHEMBL3015417 | 0.86 | ESRRG (0.56) | LTB4RLTB4R2ESRRGKMT2AKDM4E | |
| SCHEMBL30264506 | 0.86 | LTB4R (0.46) | LTB4RLTB4R2ESRRGPPARDPPARA | |
| SCHEMBL2240309 | 0.86 | PPARA (0.44) | LTB4RLTB4R2ESRRGPPARACTSK | |
| SCHEMBL30954592 | 0.85 | AOC3 (0.47) | ESRRGPPARDPPARARAB9ASMN1; SMN2 | |
| SCHEMBL30954590 | 0.85 | AOC3 (0.47) | ESRRGPPARDPPARARAB9ASMN1; SMN2 | |
| SCHEMBL30277846 | 0.85 | ESRRG (0.48) | LTB4RLTB4R2ESRRGAAK1CTSK | |
| SCHEMBL22777273 | 0.85 | ESRRG (0.42) | LTB4RLTB4R2ESRRGPPARACTSK | |
| SCHEMBL21996922 | 0.85 | ESRRG (0.42) | LTB4RLTB4R2ESRRGCTSKPDK2 | |
| SCHEMBL4873059 | 0.85 | ESRRG (0.42) | LTB4RLTB4R2ESRRGAAK1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20250270212-A1 | CHIMERIC COMPOUNDS USEFUL IN TREATING DISEASES | PADARN THERAPEUTICS INC (US) | 2025-08-28 | — | — | US | disclosed |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| US-12258341-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| WO-2025053163-A1 | COMPOUND OR SALT THEREOF, METHOD FOR PRODUCING SAME, PHARMACEUTICAL COMPOSITION CONTAINING COMPOUND OR SALT THEREOF, AND METHOD FOR PRODUCING SAME | セレイドセラピューティクス株式会社 | 2025-03-13 | — | — | WO | disclosed |
| EP-4416151-A1 | CHIMERIC COMPOUNDS USEFUL IN TREATING DISEASES | Padarn Therapeutics, Inc. (US) | 2024-08-21 | — | — | EP | disclosed |
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| WO-2023064164-A1 | CHIMERIC COMPOUNDS USEFUL IN TREATING DISEASES | PADARN THERAPEUTICS, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
| US-8697725-B2 | Tetrahydroquinoline derivatives and their pharmaceutical use | GLAXOSMITHKLINE LLC (US) | 2014-04-15 | — | — | US | disclosed |
| US-8697725-B2 | Tetrahydroquinoline derivatives and their pharmaceutical use | GLAXOSMITHKLINE LLC (US) | 2014-04-15 | — | — | US | disclosed |
| US-8697725-B2 | Tetrahydroquinoline derivatives and their pharmaceutical use | GLAXOSMITHKLINE LLC (US) | 2014-04-15 | — | — | US | disclosed |
| EP-2496557-B1 | TETRAHYDROQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | GLAXOSMITHKLINE LLC (US) | 2013-12-18 | — | — | EP | disclosed |
| US-20120208798-A1 | Tetrahydroquinoline Derivatives And Their Pharmaceutical Use | GLAXOSMITHKLINE LLC | 2012-08-16 | — | — | US | disclosed |
| US-20120208798-A1 | Tetrahydroquinoline Derivatives And Their Pharmaceutical Use | GLAXOSMITHKLINE LLC | 2012-08-16 | — | — | US | disclosed |
| US-20120208798-A1 | Tetrahydroquinoline Derivatives And Their Pharmaceutical Use | GLAXOSMITHKLINE LLC | 2012-08-16 | — | — | US | disclosed |
| CN-102046179-A | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS INC | 2011-05-04 | — | — | CN | disclosed |
| EP-2282742-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | Infinity Pharmaceuticals, Inc. (US) | 2011-02-16 | — | — | EP | disclosed |
| WO-2009126691-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC (US) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12258341-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | TAAR1 2050/4885LTB4R 1673/4885LTB4R2 2343/4885 |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TAAR1 2050/4885LTB4R 1673/4885LTB4R2 2343/4885 |
| US-20120208798-A1 | Tetrahydroquinoline Derivatives And Their Pharmaceutical Use | ABCB1, CYP3A7, UGT2B7 | TAAR1 3114/4885LTB4R 1027/4885LTB4R2 868/4885 |
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TAAR1 2050/4885LTB4R 1673/4885LTB4R2 2343/4885 |
| US-11807636-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | TAAR1 2050/4885LTB4R 1673/4885LTB4R2 2343/4885 |
| US-20250270212-A1 | CHIMERIC COMPOUNDS USEFUL IN TREATING DISEASES | WEE1, WEE2, PARP1 | TAAR1 4747/4885LTB4R 3831/4885LTB4R2 3810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.